Login / Signup

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Patrick Yung WenJordi A RodonWarren MasonJoseph T BeckJohn DeGrootValerie DonnetDavid MillsMona El-HashimyMark Rosenthal
Published in: ESMO open (2021)
Considering that the primary objective of estimating the MTD was not achieved in addition to the observed challenging safety profile of buparlisib in combination with radiotherapy and temozolomide, Novartis decided not to pursue the development of buparlisib in newly diagnosed glioblastoma.Trial registration numberClinicalTrials.gov identifier: NCT01473901.
Keyphrases